Weimai, a digital healthcare solutions provider in China, has raised $27.3m in a Series D funding round to expand its healthcare services to meet the increasing demand for long-term medical care.

The funding attracted new investors such as Choice Capital, CNCB Investment, Yuhang Transformation Industry Investment, Nanhu Investment and Deqing Industry Development Investment.

Existing shareholders including Cenova Ventures, Source Code Capital, and Vision+ Capital also contributed to the round.

The capital will accelerate the development of Weimai's disease management solutions and AI research initiatives.

The company's managed care organisation (MCO) model caters to a wide range of service needs following diagnosis, tests, surgery, and hospitalisation.

Weimai founder and CEO Qiu Jialin said: "Over the past nine years, we have consistently integrated MCO with the practices of China's healthcare reforms, pioneering a uniquely Chinese approach to managed care—C-MCO.

"Through technological empowerment, we have upgraded healthcare services to provide full-cycle management and closed-loop services across pre-hospital, in-hospital, and post-hospital scenarios.”

Its integrated approach combines online and offline services, as well as in-hospital and out-of-hospital care.

Yuhang Transformation Industry investment manager Chen Du said: "We firmly believe that Weimai will continue to lead industry transformation and open up a broader future for public health."

Weimai, as of 31 December 2024, has partnered with more than 2,500 public healthcare institutions and 200,000 licensed doctors, reaching a billion patients.

CareAI, a pre-trained AI model, which is central to Weimai's technology, automates health assessments and self-screenings. It was launched in 2023.

It facilitates better triage and referral processes and integrates with hospital apps and WeChat for health management advice.